Delcath Systems Inc Cash Flow Conversion Efficiency
Delcath Systems Inc cash flow conversion efficiency. Based on the latest financial reports, Delcath Systems Inc (DCTH) has a cash flow conversion efficiency ratio of 0.008x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($857.00K) by net assets ($112.71 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Delcath Systems Inc (1999–2025)
Cash flow conversion efficiency of Delcath Systems Inc from 1999 to 2025. This chart illustrates how Delcath Systems Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Delcath Systems Inc share price for real-time trading data and today's change.
Delcath Systems Inc Cash Flow Conversion Ratio Explained
Delcath Systems Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Delcath Systems Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Delcath Systems Inc ranked by their cash flow conversion efficiency. Also see Delcath Systems Inc market cap and net worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Jasmine Telecom Systems Public Company Limited
BK:JTS
|
0.120x |
|
Dhipaya Group Holdings PCL
BK:TIPH-R
|
N/A |
|
Yuanbao Inc. American Depositary Shares
NASDAQ:YB
|
0.399x |
|
LF Corp
KO:093050
|
0.034x |
|
Sysgration Ltd
TWO:5309
|
-0.013x |
|
Invesco Mortgage Capital Inc
NYSE:IVR
|
0.047x |
|
Somalogic Inc
NASDAQ:SLGC
|
-0.043x |
|
Brait SE
JSE:BAT
|
-0.002x |
Annual Cash Flow Conversion Efficiency for Delcath Systems Inc (1999–2025)
The table below shows the annual cash flow conversion efficiency of Delcath Systems Inc from 1999 to 2025. Review DCTH free cash flow generation to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $111.22 Million | $22.52 Million | 0.202x | +174.50% |
| 2024-12-31 | $68.75 Million | $-18.68 Million | -0.272x | +86.28% |
| 2023-12-31 | $15.78 Million | $-31.25 Million | -1.981x | -146.51% |
| 2022-12-31 | $-5.86 Million | $-24.95 Million | 4.258x | +325.17% |
| 2021-12-31 | $11.95 Million | $-22.60 Million | -1.891x | -82.59% |
| 2020-12-31 | $22.08 Million | $-22.87 Million | -1.036x | -127.80% |
| 2019-12-31 | $-6.36 Million | $-23.69 Million | 3.726x | +277.88% |
| 2018-12-31 | $-14.94 Million | $-14.73 Million | 0.986x | +104.34% |
| 2017-12-31 | $678.00K | $-15.40 Million | -22.711x | -338.09% |
| 2016-12-31 | $-1.49 Million | $-14.21 Million | 9.539x | +599.66% |
| 2015-12-31 | $8.60 Million | $-16.42 Million | -1.909x | -122.74% |
| 2014-12-31 | $18.14 Million | $-15.55 Million | -0.857x | +24.35% |
| 2013-12-31 | $30.10 Million | $-34.10 Million | -1.133x | +54.67% |
| 2012-12-31 | $20.01 Million | $-50.01 Million | -2.499x | -74.57% |
| 2011-12-31 | $26.10 Million | $-37.37 Million | -1.432x | -72.88% |
| 2010-12-31 | $29.08 Million | $-24.08 Million | -0.828x | -88.06% |
| 2009-12-31 | $23.76 Million | $-10.46 Million | -0.440x | +33.15% |
| 2008-12-31 | $10.21 Million | $-6.72 Million | -0.659x | -94.31% |
| 2007-12-31 | $16.43 Million | $-5.57 Million | -0.339x | +70.19% |
| 2006-12-31 | $8.09 Million | $-9.20 Million | -1.137x | -374.44% |
| 2005-12-31 | $12.60 Million | $-3.02 Million | -0.240x | +44.79% |
| 2004-12-31 | $6.79 Million | $-2.95 Million | -0.434x | +55.57% |
| 2003-12-31 | $2.17 Million | $-2.12 Million | -0.977x | +10.20% |
| 2002-12-31 | $1.64 Million | $-1.78 Million | -1.088x | -55.01% |
| 2001-12-31 | $3.23 Million | $-2.27 Million | -0.702x | -852.96% |
| 2000-12-31 | $4.91 Million | $-361.26K | -0.074x | +96.69% |
| 1999-12-31 | $490.00K | $-1.09 Million | -2.224x | -- |
About Delcath Systems Inc
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development… Read more